Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives
Open accessThe DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) and bromodomain-containing proteins (BCPs) play a key role in chromatin remodeling. Based on their ability to regulate inducible gene expression in the context of inflammation and cancer, HDACs and BCPs have been the focus of drug discovery efforts, and numerous small-molecule inhibitors have been developed. However, dose-limiting toxicities of the first generation of inhibitors, which typically target multiple HDACs or BCPs, have limited translation to the clinic. Over the last decade, an increasing effort has been dedicated to designing class-, isoform-, or domain-specific HDAC or BCP inhibitors, as well as developing strategies for cell-specific targeted drug delivery. Selective inhibition of the epigenetic modulators is helping to elucidate the functions of individual epigenetic proteins and has the potential to yield better and safer therapeutic strategies. In accordance with this idea, several in vitro and in vivo studies have reported the ability of more selective HDAC/BCP inhibitors to recapitulate the beneficial effects of pan-inhibitors with less unwanted adverse events. In this review, we summarize the most recent advances with these strategies, discussing advantages and limitations of these approaches as well as some therapeutic perspectives, focusing on autoimmune and inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Selective domain targeting of BD1 and BD2. (A) BET proteins family of BCPs comprise the ubiquitously expressed BRD2, BRD3, and BRD4 and BRDT, which all harbor two highly conserved tandem bromodomains, BD1 and BD2, allowing them to recognize acetylated lysine. (B) BD1 and BD2 have distinct functions. BD1 binding is sufficient to maintain homeostatic and oncogenic gene transcription programs, while BD2 binding is required to promote an inflammatory transcriptional response. (C) Domain-selective inhibitors for BD1 and BD2 show preferential effects on different types of cellular functions [141].](https://figures.cochat.ai/paper-figures/ce06f9e70a4c4ae0b0e25c87dfd3a566/selective-targeting-of-epigenetic-readers-and-histone-deacetylases-in-autoimmune-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These inhibitors are capable of specifically targeting categories, subtypes, and structural domains,491 potentially providing more pronounced benefits in terms of efficacy, safety, and tolerability.67”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [491]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Janczura, K. J., Volmar, C.-H., Sartor, G. C., Rao, S. J., Ricciardi, N. R., Lambert, G., Brothers, S. P., & Wahlestedt, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805436115 · Cited by 183 · cited 1×
“Inhibitors with a high degree of reported selectivity toward HDAC3, including RGFP966, MI192, and ITF3100, have been shown to efficiently attenuate inflammatory responses [33,58,59,68] and to restore LPS tolerance in inflammatory macrophages in vitro [33].”
BackgroundRetractedRegulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Inflammation and wound healing: the role of the macrophage
Koh, T. J., & DiPietro, L. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001943 · Cited by 1,667
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Macrophage Polarization in Inflammatory Diseases
Liu, Y.-C., Zou, X.-B., Chai, Y.-F., & Yao, Y.-M. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8879 · Cited by 1,085
RNA-mediated epigenetic regulation of gene expression
Holoch, D., & Moazed, D. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3863 · Cited by 1,003
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801 · cited 2×
“Tubastatin A [79] HDAC6 IC50 of 15 nM for HDAC6.”
BackgroundThe role of the transcription factor CREB in immune function
Wen, A. Y., Sakamoto, K. M., & Miller, L. S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001829 · Cited by 790
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3235 · Cited by 761
Macrophages in inflammation, repair and regeneration
Oishi, Y., & Manabe, I. (2018) · International Immunology · doi:10.1093/intimm/dxy054 · Cited by 734
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
Plasticity in binding confers selectivity in ligand-induced protein degradation
Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
Fujisawa, T., & Filippakopoulos, P. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.143 · Cited by 573
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558 · cited 1×
“TMP195 exhibited a potent effect on monocyte and macrophage activation in vitro, reducing CCL2 protein secretion and increasing the production of CCL1 by monocyte-derived macrophages and modifying human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro [55].”
BackgroundA short guide to histone deacetylases including recent progress on class II enzymes
Park, S.-Y., & Kim, J.-S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0382-4 · Cited by 509
Solomon, J. M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P. S., & Huber, L. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.28-38.2006 · Cited by 486
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Gilan, O., Rioja, I., Knezevic, K., Bell, M. J., Yeung, M. M., Harker, N. R., Lam, E. Y. N., Chung, C.-W., Bamborough, P., Petretich, M., et al. (2020) · Science · doi:10.1126/science.aaz8455 · Cited by 422
Self-citationBromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Faivre, E. J., McDaniel, K. F., Albert, D. H., Mantena, S. R., Plotnik, J. P., Wilcox, D., Zhang, L., Bui, M. H., Sheppard, G. S., Wang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-1930-8 · Cited by 408
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386 · cited 1×
“Since these first-generation inhibitors typically target multiple members of the HDAC or BET family, unwanted effects may be linked to a broad impact on transcriptional activity that extends to off-target pathways [28,29].”
BackgroundSelective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 376
Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug Design
Imai, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.173 · Cited by 359
Taniguchi, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111849 · Cited by 336
DNA Methylation Reprogramming during Mammalian Development
Zeng, Y., & Chen, T. (2019) · Genes · doi:10.3390/genes10040257 · Cited by 321
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313
Carboxylesterases in lipid metabolism: from mouse to human
Lian, J., Nelson, R., & Lehner, R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0437-z · Cited by 300
Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice
Glauben, R., Batra, A., Fedke, I., Zeitz, M., Lehr, H. A., Leoni, F., Mascagni, P., Fantuzzi, G., Dinarello, C. A., & Siegmund, B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5015 · Cited by 293
Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281
Lin, H., Hu, C., Chan, H., Liew, Y., Huang, H., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., & Clément‐Lacroix, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707165 · Cited by 272
Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253
Clinical trials for BET inhibitors run ahead of the science
Andrieu, G., Belkina, A. C., & Denis, G. V. (2016) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2016.06.004 · Cited by 247 · cited 1×
“Recently, increasing effort has been dedicated to developing inhibitors that can achieve a higher degree of selectivity in targeting the epigenetic modulators, which may alleviate safety issues that hold back their translation into clinical use [30,31].”
BackgroundTheodoulou, N. H., Bamborough, P., Bannister, A. J., Becher, I., Bit, R. A., Che, K. H., Chung, C.-W., Dittmann, A., Drewes, G., Drewry, D. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00256 · Cited by 235
Bromodomains: Structure, function and pharmacology of inhibition
Ferri, E., Petosa, C., & McKenna, C. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.005 · Cited by 229
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
Martin, L. J., Koegl, M., Bader, G., Cockcroft, X.-L., Fedorov, O., Fiegen, D., Gerstberger, T., Hofmann, M. H., Hohmann, A. F., Kessler, D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01865 · Cited by 224
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Singh, A. K., Bishayee, A., & Pandey, A. K. (2018) · Nutrients · doi:10.3390/nu10060731 · Cited by 221
Grabiec, A. M., Korchynskyi, O., Tak, P. P., & Reedquist, K. A. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.154211 · Cited by 211
Identification of small-molecule antagonists that inhibit an activator:coactivator interaction
Best, J. L., Amezcua, C. A., Mayr, B., Flechner, L., Murawsky, C. M., Emerson, B., Zor, T., Gardner, K. H., & Montminy, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406374101 · Cited by 207
Wyce, A., Ganji, G., Smitheman, K. N., Chung, C.-W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072967 · Cited by 206
Yee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 203
Histone deacetylases as targets for treatment of multiple diseases
Tang, J., Yan, H., & Zhuang, S. (2013) · Clinical Science · doi:10.1042/cs20120504 · Cited by 200
Kozikowski, A. P., Tapadar, S., Luchini, D. N., Kim, K. H., & Billadeau, D. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002894 · Cited by 189
Zuberi, R. I., Hsu, D. K., Kalayci, O., Chen, H.-Y., Sheldon, H. K., Yu, L., Apgar, J. R., Kawakami, T., Lilly, C. M., & Liu, F.-T. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63255-5 · Cited by 184
Jochems, J., Boulden, J., Lee, B. G., Blendy, J. A., Jarpe, M., Mazitschek, R., Van Duzer, J. H., Jones, S., & Berton, O. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.207 · Cited by 166
Moradei, O. M., Mallais, T. C., Frechette, S., Paquin, I., Tessier, P. E., Leit, S. M., Fournel, M., Bonfils, C., Trachy-Bourget, M.-C., Liu, J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701079h · Cited by 166 · cited 5×
“Tacedinaline (CI994) [40] Class I HDAC IC50s of 0.”
BackgroundInfluentialEpigenetic regulation: A new frontier for biomedical engineers
Chen, Z., Li, S., Subramaniam, S., Shyy, J. Y.-J., & Chien, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044720 · Cited by 163
Angiolilli, C., Kabala, P. A., Grabiec, A. M., Van Baarsen, I. M., Ferguson, B. S., García, S., Malvar Fernandez, B., McKinsey, T. A., Tak, P. P., Fossati, G., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209064 · Cited by 148
Gillespie, J., Savic, S., Wong, C., Hempshall, A., Inman, M., Emery, P., Grigg, R., & McDermott, M. F. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33382 · Cited by 146
A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes
Baud, M. G. J., Lin-Shiao, E., Cardote, T., Tallant, C., Pschibul, A., Chan, K.-H., Zengerle, M., Garcia, J. R., Kwan, T. T.-L., Ferguson, F. M., et al. (2014) · Science · doi:10.1126/science.1249830 · Cited by 141
Role of Epigenetics in Inflammation-Associated diseases
Shanmugam, M. K., & Sethi, G. (2013) · Subcellular Biochemistry · doi:10.1007/978-94-007-4525-4_27 · Cited by 141 · cited 1×
“The critical role of epigenetic mechanisms in regulating gene expression in the immune system is well established, and the dysregulation of epigenetic control contributes to the development of a variety of human diseases [4,5].”
BackgroundChen, X., Wales, P., Quinti, L., Zuo, F., Moniot, S., Herisson, F., Rauf, N. A., Wang, H., Silverman, R. B., Ayata, C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116919 · Cited by 138
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
Boumber, Y., Younes, A., & Garcia-Manero, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.577737 · Cited by 134
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Zhang, G., Plotnikov, A. N., Rusinova, E., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M., & Zhou, M.-M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401334s · Cited by 132
Miller, T. C. R., Simon, B., Rybin, V., Grötsch, H., Curtet, S., Khochbin, S., Carlomagno, T., & Müller, C. W. (2016) · Nature Communications · doi:10.1038/ncomms13855 · Cited by 132
Leus, N. G. J., van der Wouden, P. E., van den Bosch, T., Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E. M., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.03.010 · Cited by 131 · cited 1×
“Inhibitors with a high degree of reported selectivity toward HDAC3, including RGFP966, MI192, and ITF3100, have been shown to efficiently attenuate inflammatory responses [33,58,59,68] and to restore LPS tolerance in inflammatory macrophages in vitro [33].”
BackgroundNadeem, A., Al-Harbi, N. O., Al-Harbi, M. M., El‐Sherbeeny, A. M., Ahmad, S. F., Siddiqui, N. M., Ansari, M. A., Zoheir, K. M. A., Attia, S. M., Alhosaini, K. A., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.001 · Cited by 130
Xu, Z., Tong, Q., Zhang, Z., Wang, S., Zheng, Y., Liu, Q., Qian, L.-B., Chen, S.-Y., Sun, J., & Cai, L. (2017) · Clinical Science · doi:10.1042/cs20170064 · Cited by 129
Vishwakarma, S., Iyer, L. R., Muley, M. M., Singh, P., Shastry, A., Saxena, A., Kulathingal, J., Vijaykanth, G., Raghul, J., Rajesh, N., et al. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.03.016 · Cited by 124
HDAC11 is a regulator of diverse immune functions
Yanginlar, C., & Logie, C. (2017) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.12.002 · Cited by 124
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J. O., & Silver, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13008 · Cited by 120
Loo, C.-S., Gatchalian, J., Liang, Y., Leblanc, M., Xie, M., Ho, J., Venkatraghavan, B., Hargreaves, D. C., & Zheng, Y. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.011 · Cited by 120
Entinostat for treatment of solid tumors and hematologic malignancies
Knipstein, J., & Gore, L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.613822 · Cited by 110 · cited 1×
“However, further evaluation found that the cardiac events were not related to Mocetinostat [50], while for Entinostat cardiac events were attributed to disparities in drug pharmacokinetics compared with preclinical models, which was mitigated upon redesigning the treatment regimens [51,52].”
BackgroundThe role of the innate immune response in autoimmune disease
Lang, K. S., Burow, A., Kurrer, M. O., Lang, P. A., & Recher, M. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.07.018 · Cited by 109
Liu, Z., Tian, B., Chen, H., Wang, P., Brasier, A. R., & Zhou, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.006 · Cited by 107
The Histone Modification Code in the Pathogenesis of Autoimmune Diseases
Araki, Y., & Mimura, T. (2017) · Mediators of Inflammation · doi:10.1155/2017/2608605 · Cited by 107
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
Morgado‐Pascual, J. L., Rayego‐Mateos, S., Tejedor-Santamaria, L., Suárez-Álvarez, B., & Ruiz‐Ortega, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01315 · Cited by 103
Pavlik, C. M., Wong, C. Y. B., Ononye, S. N., Lopéz, D., Engene, N., McPhail, K. L., Gerwick, W. H., & Balunas, M. J. (2013) · Journal of Natural Products · doi:10.1021/np400198r · Cited by 103
Zhang, M., Zhao, Q., Xia, M., Chen, J., Chen, Y., Cao, X., Liu, Y., Yuan, Z., Wang, X., & Xu, Y. (2020) · The FASEB Journal · doi:10.1096/fj.201900394rrr · Cited by 101
Zhang, S., Xu, W., Wang, H., Cao, M., Li, M., Zhao, J., Hu, Y., Wang, Y., Li, S., Xie, Y., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12673 · Cited by 96
Bromodomain Drug Discovery – the Past, the Present, and the Future
Pervaiz, M., Mishra, P., & Günther, S. (2018) · The Chemical Record · doi:10.1002/tcr.201800074 · Cited by 94
Chan, C., Fang, C., Qiao, Y., Yarilina, A., Prinjha, R. K., & Ivashkiv, L. B. (2014) · European Journal of Immunology · doi:10.1002/eji.201444862 · Cited by 84
Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis
Cantley, M. D., Fairlie, D. P., Bartold, P. M., Marino, V., Gupta, P. K., & Haynes, D. R. (2015) · Rheumatology · doi:10.1093/rheumatology/kev022 · Cited by 81
HDAC inhibitor therapy in autoimmunity and transplantation
Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y., & Wang, L. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200593 · Cited by 80
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y., & He, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190122144949 · Cited by 80
Epigenetics and the adaptive immune response
Kondilis-Mangum, H. D., & Wade, P. A. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.008 · Cited by 77
Huang, W., Wang, Y., Chao, S., Yang, C., Chen, L., Lin, M., Hou, W., Chen, M., Lee, T., Yang, P., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200300 · Cited by 76
Leus, N. G. J., van den Bosch, T., van der Wouden, P. E., Krist, K., Ourailidou, M. E., Eleftheriadis, N., Kistemaker, L. E. M., Bos, S., Gjaltema, R. A. F., Mekonnen, S. A., et al. (2017) · Scientific Reports · doi:10.1038/srep45047 · Cited by 76
HDAC3 Mediates the Inflammatory Response and LPS Tolerance in Human Monocytes and Macrophages
Ghiboub, M., Zhao, J., Yim, A. Y. F. L., Schilderink, R., Verseijden, C., van Hamersveld, P. H. P., Duarte, J. M., Hakvoort, T. B. M., Admiraal, I., Harker, N., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.550769 · Cited by 75
Self-citationActivity-Guided Design of HDAC11-Specific Inhibitors
Son, S. I., Cao, J., Zhu, C.-L., Miller, S. P., & Lin, H. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00292 · Cited by 74
Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat
Veggel, M. V., Westerman, E. M., & Hamberg, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0565-x · Cited by 72
Histone deacetylase 5 regulates the inflammatory response of macrophages
Poralla, L., Stroh, T., Erben, U., Sittig, M., Liebig, S., Siegmund, B., & Glauben, R. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12595 · Cited by 71
Drug Targeting to Monocytes and Macrophages Using Esterase-Sensitive Chemical Motifs
Needham, L. A., Davidson, A. H., Bawden, L. J., Belfield, A. J., Bone, E. A., Brotherton, D. H., Bryant, S., Charlton, M. H., Clark, V. L., Davies, S. J., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183640 · Cited by 71
Friedrich, M., Gerbeth, L., Gerling, M., Rosenthal, R., Steiger, K., Weidinger, C., Keye, J., Wu, H., Schmidt, F., Weichert, W., et al. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0135-7 · Cited by 71
Therapeutic effects of histone deacetylase inhibitors in a murine asthma model
Ren, Y., Su, X., Kong, L., Li, M., Zhao, X., Yu, N., & Kang, J. (2016) · Inflammation Research · doi:10.1007/s00011-016-0984-4 · Cited by 68
Marié, I. J., Chang, H.-M., & Levy, D. E. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180520 · Cited by 67
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, F., Zwinderman, M., & Dekker, F. (2018) · Molecules · doi:10.3390/molecules23030551 · Cited by 66
Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation
Tsuji, G., Okiyama, N., Villarroel, V. A., & Katz, S. I. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.002 · Cited by 65
Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model
Li, Y., Zhao, T., Liu, B., Halaweish, I. F., Mazitschek, R., Duan, X., & Alam, H. B. (2015) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000000510 · Cited by 65
Choi, E. W., Song, J. W., Ha, N., Choi, Y. I., & Kim, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-35602-1 · Cited by 65
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 65
Chekler, E. L. P., Pellegrino, J. A., Lanz, T. A., Denny, R. A., Flick, A. C., Coe, J. W., Langille, J., Basak, A., Liu, S., Stock, I. A., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.10.013 · Cited by 64
Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors
Shultz, M. D., Cao, X., Chen, C. H., Cho, Y. S., Davis, N. R., Eckman, J., Fan, J., Fekete, A., Firestone, B., Flynn, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200388e · Cited by 64
Targeted inhibition of histone deacetylase 6 in inflammatory diseases
Ran, J., & Zhou, J. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12974 · Cited by 64
Taniguchi, Y. (2016) · Preprints.org · doi:10.20944/preprints201610.0100.v1 · Cited by 64
Zhang, H., Ji, L., Yang, Y., Wei, Y., Zhang, X., Gang, Y., Lu, J., & Bai, L. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01060 · Cited by 61
Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury
Zhang, W., Guan, Y., Bayliss, G. P., & Zhuang, S. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00405.2020 · Cited by 59
Jahagirdar, R., Attwell, S., Marusic, S., Bendele, A., Shenoy, N., McLure, K. G., Gilham, D., Norek, K., Hansen, H. C., Yu, R., et al. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.110379 · Cited by 58
Peripheral blood methylation profiling of female Crohn’s disease patients
Yim, A. Y. F. L., Duijvis, N. W., Zhao, J., de Jonge, W. J., D’Haens, G., Mannens, M. M. A. M., Mul, A. N. P. M., Velde, A. A. T., & Henneman, P. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0230-5 · Cited by 58
Kopljar, I., Gallacher, D. J., Bondt, A. D., Cougnaud, L., Vlaminckx, E., den Wyngaert, I. V., & Lu, H. R. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0279 · Cited by 57
Liu, L., Zhou, X., Shetty, S., Hou, G., Wang, Q., & Fu, J. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.03.017 · Cited by 57
Cui, S.-N., Chen, Z.-Y., Yang, X., Chen, L., Yang, Y., Pan, S., Wang, Y., Xu, J., Zhou, T., Xiao, H., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105973 · Cited by 57
Tian, B., Liu, Z., Litvinov, J., Maroto, R., Jamaluddin, M., Rytting, E., Patrikeev, I., Ochoa, L., Vargas, G., Motamedi, M., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0445oc · Cited by 56
Park, J. K., Jang, Y. J., Oh, B. R., Shin, J., Bae, D., Ha, N., Choi, Y. I., Youn, G. S., Park, J., Lee, E. Y., et al. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02258-0 · Cited by 56
Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice
Regna, N. L., Vieson, M. D., Luo, X., Chafin, C. B., Puthiyaveetil, A. G., Hammond, S. E., Caudell, D. L., Jarpe, M. B., & Reilly, C. M. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.11.007 · Cited by 54
Li, P., Ninomiya, H., Kurata, Y., Kato, M., Miake, J., Yamamoto, Y., Igawa, O., Nakai, A., Higaki, K., Toyoda, F., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.227835 · Cited by 53
Mohmand, N. A., Choijookhuu, N., Takagi, H., Srisowanna, N., Huynh, M., Yamaguchi, Y., Oo, P. S., Myat, T. H. K., Sato, K., Yamaguchi, R., et al. (2018) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.17033 · Cited by 53
Therapeutic potential of selective histone deacetylase 3 inhibition
Zhang, L., Chen, Y., Jiang, Q., Song, W., & Zhang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.072 · Cited by 51
Do, A., Reid, R. C., Lohman, R., Sweet, M. J., Fairlie, D. P., & Iyer, A. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236711 · Cited by 51
Meier, J. C., Tallant, C., Fedorov, O., Witwicka, H., Hwang, S., van Stiphout, R. G. P. M., Lambert, J., Rogers, C. M., Yapp, C., Gerstenberger, B. S., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00481 · Cited by 51
Zhang, J., Xu, Z., Gu, J., Jiang, S., Liu, Q., Zheng, Y., Freedman, J. H., Sun, J., & Cai, L. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2017 · Cited by 49
The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A
Sima, X., He, J., Peng, J., Xu, Y., Zhang, F., & Deng, L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222305 · Cited by 48
Ryu, Y., Kee, H. J., Sun, S., Seok, Y. M., Choi, S. Y., Kim, G. R., Kee, S., Pflieger, M., Kurz, T., Kim, H.-S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213186 · Cited by 47
Ossenkoppele, G. J., Lowenberg, B., Zachee, P., Vey, N., Breems, D., Van de Loosdrecht, A. A., Davidson, A. H., Wells, G., Needham, L., Bawden, L., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12359 · Cited by 47
Zhang, H., Zhang, W., Jiao, F., Li, X., Zhang, H., Wang, L., & Gong, Z. (2018) · Medical Science Monitor · doi:10.12659/msm.906362 · Cited by 46
Zhang, W., Zhang, H., Jiao, F., Wang, L.-W., Zhang, H., & Gong, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.103 · Cited by 44
Entinostat (SNDX-275) for the treatment of non-small cell lung cancer
Ruiz, R., Raez, L. E., & Rolfo, C. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1056779 · Cited by 43
Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia
Dawson, M. A., Prinjha, R., Dittman, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S., Chung, C.-W., Hopf, C., Savitski, M., et al. (2011) · Blood · doi:10.1182/blood.v118.21.55.55 · Cited by 43
Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models
Fan, X., Zhang, H., Cheng, Y., Jiang, X., Zhu, J., & Jin, T. (2016) · Mediators of Inflammation · doi:10.1155/2016/8489251 · Cited by 42
Igoe, N., Bayle, E. D., Tallant, C., Fedorov, O., Meier, J. C., Savitsky, P. A., Rogers, C. M., Morias, Y., Scholze, S., Boyd, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00611 · Cited by 42
Rudman, M. D., Choi, J. S., Lee, H. E., Tan, S. K., Ayad, N. G., & Lee, J. K. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.08.005 · Cited by 41
Liao, W., Sun, J., Liu, W., Li, W., Jia, J., Ou, F., Su, K., Zheng, Y.-H., Zhang, Z., & Sun, Y.-P. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27873 · Cited by 40
Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
Kutil, Z., Mikešová, J., Zessin, M., Meleshin, M., Nováková, Z., Alquicer, G., Kozikowski, A., Sippl, W., Bařinka, C., & Schutkowski, M. (2019) · ACS Omega · doi:10.1021/acsomega.9b02808 · Cited by 39
Lee, J., Hong, E., Jeong, H., Hwang, J. W., Kim, H., Bae, E., Ahn, J. K., Choi, Y., Han, J., Cha, H., et al. (2014) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12501 · Cited by 37
Schilderink, R., Bell, M. J., Reginato, E., Patten, C., Rioja, I., Hilbers, F. W., Kabala, P. A., Reedquist, K. A., Tough, D. F., Tak, P. P., et al. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.09.010 · Cited by 37
Self-citationLee, J. W., Lee, S.-M., Chun, J., Im, J. P., Seo, S., Ha, N., Choi, Y. I., & Kim, J. S. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz317 · Cited by 37
Loh, Z., Fitzsimmons, R. L., Reid, R. C., Ramnath, D., Clouston, A. D., Gupta, P. K., Irvine, K. M., Powell, E. E., Schroder, K., Stow, J. L., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14768 · Cited by 36
Structural features and inhibitors of bromodomains
Meslamani, J. E., Smith, S. G., Sánchez, R., & Zhou, M. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.09.001 · Cited by 35
Bombardo, M., Saponara, E., Malagola, E., Chen, R., Seleznik, G. M., Haumaître, C., Quilichini, E., Zabel, A., Reding, T., Graf, R., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13984 · Cited by 35
Copsel, S. N., Lightbourn, C. O., Barreras, H., Lohse, I., Wolf, D., Bader, C. S., Manov, J. J., Kale, B. J., Shah, D., Brothers, S. P., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03104 · Cited by 34
Jiao, F., Wang, Y., Zhang, H., Zhang, W., Wang, L.-W., & Gong, Z. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2532-9 · Cited by 33
LoPresti, P. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00519 · Cited by 33
Next-generation epigenetic inhibitors
Filippakopoulos, P., & Knapp, S. (2020) · Science · doi:10.1126/science.abb5060 · Cited by 29
Walewski, J. A., Paszkiewicz‐Kozik, E., Borsaru, G., Hellmann, A. R., Janíková, A., Warszewska, A., Mais, A., Ammendola, A., Herz, T., Krauss, B., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1492122 · Cited by 28
Zhang, W., Sun, X., Ba, G., Tang, R., & Lin, H. P. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107400 · Cited by 28
Zhou, W., Yang, J., Saren, G., Zhao, H., Cao, K., Fu, S., Pan, X., Zhang, H., Wang, A., & Chen, X. (2020) · Theranostics · doi:10.7150/thno.44961 · Cited by 27
The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus
Ren, J., Panther, E. J., Liao, X., Grammer, A. C., Lipsky, P. E., & Reilly, C. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124007 · Cited by 27
Lin, F., Yen, J.-L., Kuo, Y.-C., Kang, J., Cheng, Y., Huang, W., & Hsiao, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020410 · Cited by 26
Takeba, Y., Suzuki, N., Wakisaka, S., Takeno, M., Kaneko, A., Asai, T., & Sakane, T. (2000) · PubMed · Cited by 25
Ghiboub, M., Köster, J., Craggs, P. D., Yim, A. Y. F. L., Shillings, A., Hutchinson, S., Bingham, R. P., Gatfield, K. M., Hageman, I., Yao, G., et al. (2022) · BMC Biology · doi:10.1186/s12915-022-01380-6 · Cited by 25
Self-citationCao, F., Zwinderman, M. R. H., van Merkerk, R., Ettema, P. E., Quax, W. J., & Dekker, F. J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.038 · Cited by 24
A Highly Potent and Selective Histone Deacetylase 6 Inhibitor Prevents DSS-Induced Colitis in Mice
Liu, T., Wang, R., Xu, H., Song, Y., & Qi, Y. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-01023 · Cited by 24
Luque-Martin, R., den Bossche, J. V., Furze, R. C., Neele, A. E., van der Velden, S., Gijbels, M. J., van Roomen, C. P. A. A., Bernard, S. G., de Jonge, W. J., Rioja, I., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01242 · Cited by 24
Jan, J., Chou, Y.-C., Cheng, Y., Chen, C., Huang, W., & Hsiao, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071394 · Cited by 19
A phase I study of resminostat in Japanese patients with advanced solid tumors
Kitazono, S., Fujiwara, Y., Nakamichi, S., Mizugaki, H., Nokihara, H., Yamamoto, N., Yamada, Y., Inukai, E., Nakamura, O., & Tamura, T. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2741-8 · Cited by 18
Ellis, J. D., Neil, D., Inston, N. G., Jenkinson, E. J., Drayson, M. T., Hampson, P., Shuttleworth, S. J., Ready, A. R., & Cobbold, M. (2016) · Transplantation · doi:10.1097/tp.0000000000001208 · Cited by 17
In situ Detection of Human Monocyte/ Macrophage Serine Esterase-1 mRNA Expression in Human Tissues
Satoh, T., Hemmerlein, B., Zschunke, F., & Radzun, H. (1999) · Pathobiology · doi:10.1159/000028066 · Cited by 15
Lv, Q., Yang, A., Shi, W., Chen, F., Liu, Y., Liu, Y., & Wang, D. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0564-0 · Cited by 15
Lei, L., Bai, G., Wang, X., Liu, S., Xia, J., Wu, S., Huan, Y., & Shen, Z. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115189 · Cited by 11
Guo, D., Hong, D., Wang, P., Wang, J., Chen, L., Zhao, W., Zhang, L., Yao, C., Chu, B., Chen, S., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.021 · Cited by 10
Ghiboub, M., Köster, J., Craggs, P. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.10.239475 · Cited by 6
Self-citationElfiky, A. M. I., Ghiboub, M., van Hamersveld, P. H. P., Welting, O., Admiraal, I., Rahman, S., de Winther, M. P. J., Becker, M. A. J., Wildenberg, M. E., Furze, R. C., et al. (2020) · Gastroenterology · doi:10.1016/s0016-5085(20)32645-7 · Cited by 1
Self-citationPark, J. K., Jang, Y. J., Oh, B. R., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-27342/v1 · Cited by 1
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Old age as a risk factor for liver diseases: Modern therapeutic approaches
Georgieva, M., Xenodochidis, C., & Krasteva, N. A. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112334 · Cited by 70
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections
Bhat, M. F., Srdanović, S., Sundberg, L.-R., Einarsdottir, H., Marjomäki, V., & Dekker, F. J. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104193 · Cited by 49
New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
Luan, Y., Liu, H., Luan, Y., Yang, Y., Yang, J., & Ren, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863677 · Cited by 34
Kadier, K., Niu, T., Ding, B., Chen, B., Qi, X., Chen, D., Cheng, X., Fang, Y.-Z., Zhou, J., Zhao, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202309459 · Cited by 31
Metadata
- Authors
- Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
- Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centers, University of Amsterdam, 1105 BK Amsterdam, The Netherlands
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-04-23
- Volume
- 11
- Issue
- 5
- Pages
- 336
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8145108
- OpenAlex
- W3159535985
- Cited by
- 28
- References
- 161
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 2
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Commission (HORIZON2020, 641665)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase, epigenetic reader protein, selective inhibitors, isoform-selective inhibitors, chromatin remodeling, autoimmune disease, inflammatory diseases, histone deacetylase inhibitors, bromodomain inhibitors, drug toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.